Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

Seungho Lim, Jooho Park, Man Kyu Shim, Wooram Um, Hong Yeol Yoon, Ju Hee Ryu, Dong Kwon Lim, Kwangmeyung Kim

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Cancer immunotherapy is an attractive treatment option under clinical settings. However, the major challenges of immunotherapy include limited patient response, limited tumor specificity, immune-related adverse events, and immunosuppressive tumor microenvironment. Therefore, nanoparticle (NP)-based drug delivery has been used to not only increase the efficacy of immunotherapeutic agents, but it also significantly reduces the toxicity. In particular, NP-based drug delivery systems alter the pharmacokinetic (PK) profile of encapsulated or conjugated immunotherapeutic agents to targeted cancer cells or immune cells and facilitate the delivery of multiple therapeutic combinations to targeted cells using single NPs. Recently, advanced NP-based drug delivery systems were effectively utilized in cancer immunotherapy to reduce the toxic side effects and immune-related adverse events. Repurposing these NPs as delivery systems of immunotherapeutic agents may overcome the limitations of current cancer immunotherapy. In this review, we focus on recent advances in NP-based immunotherapeutic delivery systems, such as immunogenic cell death (ICD)-inducing drugs, cytokines and adjuvants for promising cancer immunotherapy. Finally, we discuss the challenges facing current NP-based drug delivery systems that need to be addressed for successful clinical application.

Original languageEnglish
Pages (from-to)7906-7923
Number of pages18
JournalTheranostics
Volume9
Issue number25
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Drug Delivery Systems
Immunotherapy
Nanoparticles
Neoplasms
Tumor Microenvironment
Poisons
Immunosuppressive Agents
Pharmaceutical Preparations
Cell Death
Pharmacokinetics
Cytokines
Therapeutics

Keywords

  • Adjuvants
  • Cancer immunotherapy
  • Cytokines
  • Drug delivery system
  • Immunogenic cell death
  • Nanoparticles

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. / Lim, Seungho; Park, Jooho; Shim, Man Kyu; Um, Wooram; Yoon, Hong Yeol; Ryu, Ju Hee; Lim, Dong Kwon; Kim, Kwangmeyung.

In: Theranostics, Vol. 9, No. 25, 01.01.2019, p. 7906-7923.

Research output: Contribution to journalReview article

Lim, Seungho ; Park, Jooho ; Shim, Man Kyu ; Um, Wooram ; Yoon, Hong Yeol ; Ryu, Ju Hee ; Lim, Dong Kwon ; Kim, Kwangmeyung. / Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. In: Theranostics. 2019 ; Vol. 9, No. 25. pp. 7906-7923.
@article{b6908dca811f4668bf836644a75a653f,
title = "Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy",
abstract = "Cancer immunotherapy is an attractive treatment option under clinical settings. However, the major challenges of immunotherapy include limited patient response, limited tumor specificity, immune-related adverse events, and immunosuppressive tumor microenvironment. Therefore, nanoparticle (NP)-based drug delivery has been used to not only increase the efficacy of immunotherapeutic agents, but it also significantly reduces the toxicity. In particular, NP-based drug delivery systems alter the pharmacokinetic (PK) profile of encapsulated or conjugated immunotherapeutic agents to targeted cancer cells or immune cells and facilitate the delivery of multiple therapeutic combinations to targeted cells using single NPs. Recently, advanced NP-based drug delivery systems were effectively utilized in cancer immunotherapy to reduce the toxic side effects and immune-related adverse events. Repurposing these NPs as delivery systems of immunotherapeutic agents may overcome the limitations of current cancer immunotherapy. In this review, we focus on recent advances in NP-based immunotherapeutic delivery systems, such as immunogenic cell death (ICD)-inducing drugs, cytokines and adjuvants for promising cancer immunotherapy. Finally, we discuss the challenges facing current NP-based drug delivery systems that need to be addressed for successful clinical application.",
keywords = "Adjuvants, Cancer immunotherapy, Cytokines, Drug delivery system, Immunogenic cell death, Nanoparticles",
author = "Seungho Lim and Jooho Park and Shim, {Man Kyu} and Wooram Um and Yoon, {Hong Yeol} and Ryu, {Ju Hee} and Lim, {Dong Kwon} and Kwangmeyung Kim",
year = "2019",
month = "1",
day = "1",
doi = "10.7150/thno.38425",
language = "English",
volume = "9",
pages = "7906--7923",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "25",

}

TY - JOUR

T1 - Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

AU - Lim, Seungho

AU - Park, Jooho

AU - Shim, Man Kyu

AU - Um, Wooram

AU - Yoon, Hong Yeol

AU - Ryu, Ju Hee

AU - Lim, Dong Kwon

AU - Kim, Kwangmeyung

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer immunotherapy is an attractive treatment option under clinical settings. However, the major challenges of immunotherapy include limited patient response, limited tumor specificity, immune-related adverse events, and immunosuppressive tumor microenvironment. Therefore, nanoparticle (NP)-based drug delivery has been used to not only increase the efficacy of immunotherapeutic agents, but it also significantly reduces the toxicity. In particular, NP-based drug delivery systems alter the pharmacokinetic (PK) profile of encapsulated or conjugated immunotherapeutic agents to targeted cancer cells or immune cells and facilitate the delivery of multiple therapeutic combinations to targeted cells using single NPs. Recently, advanced NP-based drug delivery systems were effectively utilized in cancer immunotherapy to reduce the toxic side effects and immune-related adverse events. Repurposing these NPs as delivery systems of immunotherapeutic agents may overcome the limitations of current cancer immunotherapy. In this review, we focus on recent advances in NP-based immunotherapeutic delivery systems, such as immunogenic cell death (ICD)-inducing drugs, cytokines and adjuvants for promising cancer immunotherapy. Finally, we discuss the challenges facing current NP-based drug delivery systems that need to be addressed for successful clinical application.

AB - Cancer immunotherapy is an attractive treatment option under clinical settings. However, the major challenges of immunotherapy include limited patient response, limited tumor specificity, immune-related adverse events, and immunosuppressive tumor microenvironment. Therefore, nanoparticle (NP)-based drug delivery has been used to not only increase the efficacy of immunotherapeutic agents, but it also significantly reduces the toxicity. In particular, NP-based drug delivery systems alter the pharmacokinetic (PK) profile of encapsulated or conjugated immunotherapeutic agents to targeted cancer cells or immune cells and facilitate the delivery of multiple therapeutic combinations to targeted cells using single NPs. Recently, advanced NP-based drug delivery systems were effectively utilized in cancer immunotherapy to reduce the toxic side effects and immune-related adverse events. Repurposing these NPs as delivery systems of immunotherapeutic agents may overcome the limitations of current cancer immunotherapy. In this review, we focus on recent advances in NP-based immunotherapeutic delivery systems, such as immunogenic cell death (ICD)-inducing drugs, cytokines and adjuvants for promising cancer immunotherapy. Finally, we discuss the challenges facing current NP-based drug delivery systems that need to be addressed for successful clinical application.

KW - Adjuvants

KW - Cancer immunotherapy

KW - Cytokines

KW - Drug delivery system

KW - Immunogenic cell death

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85074354307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074354307&partnerID=8YFLogxK

U2 - 10.7150/thno.38425

DO - 10.7150/thno.38425

M3 - Review article

C2 - 31695807

AN - SCOPUS:85074354307

VL - 9

SP - 7906

EP - 7923

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 25

ER -